Skip to main content

Table 1 Distribution of patients from stages 2-4 into stages A-D and substages C1-D3

From: Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial

 

GOLD 2

GOLD 3

GOLD 4

 

n = 2611 (46% of total)

n = 2529 (45% of total)

n = 490 (9% of total)

A

356 (14% of GOLD2)

-

-

B

1421 (54%)

-

-

C

89 (3%)

195 (8%)

12 (2%)

D

745 (29%)

2334 (92%)

478 (98%)

C1 *

-

147 (6%)

6 (1%)

C2 *

89 (3%)

-

-

C3 *

-

48 (2%)

6 (1%)

D1 *

 

1317 (52%)

246 (50%)

D2 *

745 (15%)

 

-

D3 *

 

1017 (40%)

232 (47%)

  1. * C1/D1, high risk is based on FEV1<50% only; C2/D2, based on history of frequent exacerbations only; C3/D3, based on both.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us